Cargando…
Novel ultra-small micelles based on ginsenoside Rb1: a potential nanoplatform for ocular drug delivery
Objectives: Ginsenosides Rb1 (Rb1) could form micelles in aqueous solutions. Self-assembled Rb1 micelles could potentially be utilized as ocular drug delivery system, and it was postulated that the encapsulation of a medicine within Rb1 micelles might strengthen the drug’s therapeutic action and red...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461112/ https://www.ncbi.nlm.nih.gov/pubmed/30957571 http://dx.doi.org/10.1080/10717544.2019.1600077 |
_version_ | 1783410447575154688 |
---|---|
author | Li, Mengshuang Lan, Jie Li, Xuefei Xin, Meng Wang, Hui Zhang, Fan Lu, Xiaohong Zhuang, Zengfang Wu, Xianggen |
author_facet | Li, Mengshuang Lan, Jie Li, Xuefei Xin, Meng Wang, Hui Zhang, Fan Lu, Xiaohong Zhuang, Zengfang Wu, Xianggen |
author_sort | Li, Mengshuang |
collection | PubMed |
description | Objectives: Ginsenosides Rb1 (Rb1) could form micelles in aqueous solutions. Self-assembled Rb1 micelles could potentially be utilized as ocular drug delivery system, and it was postulated that the encapsulation of a medicine within Rb1 micelles might strengthen the drug’s therapeutic action and reduce side effects. Methods: Diclofenac-loaded Rb1 micelles (Rb1-Dic micelles) were formulated, optimized, and then further evaluated for in vitro cytotoxicity/in vivo ocular irritation, in vivo corneal permeation, and in vivo anti-inflammatory efficacy. Results: Rb1 self-assembled into micelles with ultra-small particle size (<8 nm) in a homogeneous distribution state (polydispersity index [PDI] < 0.3). Diclofenac was highly encapsulated into the micelles according to the weight ratios of Rb1 to diclofenac. The ophthalmic solution of Rb1-Dic micelle was simple to prepare. Rb1 had good cellular tolerance, and it also improved the cellular tolerance of the encapsulated diclofenac. Rb1-Dic micelles also showed non-irritants to the rabbit eyes. The use of Rb1 micelles significantly improved the in vivo corneal permeation as well as the anti-inflammatory efficacy of diclofenac when compared to commercial diclofenac eye drops. Conclusion: Rb1 micelle formulations have great potential as a novel ocular drug delivery system to improve the bioavailability of drugs such as diclofenac. |
format | Online Article Text |
id | pubmed-6461112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-64611122019-04-19 Novel ultra-small micelles based on ginsenoside Rb1: a potential nanoplatform for ocular drug delivery Li, Mengshuang Lan, Jie Li, Xuefei Xin, Meng Wang, Hui Zhang, Fan Lu, Xiaohong Zhuang, Zengfang Wu, Xianggen Drug Deliv Research Article Objectives: Ginsenosides Rb1 (Rb1) could form micelles in aqueous solutions. Self-assembled Rb1 micelles could potentially be utilized as ocular drug delivery system, and it was postulated that the encapsulation of a medicine within Rb1 micelles might strengthen the drug’s therapeutic action and reduce side effects. Methods: Diclofenac-loaded Rb1 micelles (Rb1-Dic micelles) were formulated, optimized, and then further evaluated for in vitro cytotoxicity/in vivo ocular irritation, in vivo corneal permeation, and in vivo anti-inflammatory efficacy. Results: Rb1 self-assembled into micelles with ultra-small particle size (<8 nm) in a homogeneous distribution state (polydispersity index [PDI] < 0.3). Diclofenac was highly encapsulated into the micelles according to the weight ratios of Rb1 to diclofenac. The ophthalmic solution of Rb1-Dic micelle was simple to prepare. Rb1 had good cellular tolerance, and it also improved the cellular tolerance of the encapsulated diclofenac. Rb1-Dic micelles also showed non-irritants to the rabbit eyes. The use of Rb1 micelles significantly improved the in vivo corneal permeation as well as the anti-inflammatory efficacy of diclofenac when compared to commercial diclofenac eye drops. Conclusion: Rb1 micelle formulations have great potential as a novel ocular drug delivery system to improve the bioavailability of drugs such as diclofenac. Taylor & Francis 2019-04-08 /pmc/articles/PMC6461112/ /pubmed/30957571 http://dx.doi.org/10.1080/10717544.2019.1600077 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Li, Mengshuang Lan, Jie Li, Xuefei Xin, Meng Wang, Hui Zhang, Fan Lu, Xiaohong Zhuang, Zengfang Wu, Xianggen Novel ultra-small micelles based on ginsenoside Rb1: a potential nanoplatform for ocular drug delivery |
title | Novel ultra-small micelles based on ginsenoside Rb1: a potential nanoplatform for ocular drug delivery |
title_full | Novel ultra-small micelles based on ginsenoside Rb1: a potential nanoplatform for ocular drug delivery |
title_fullStr | Novel ultra-small micelles based on ginsenoside Rb1: a potential nanoplatform for ocular drug delivery |
title_full_unstemmed | Novel ultra-small micelles based on ginsenoside Rb1: a potential nanoplatform for ocular drug delivery |
title_short | Novel ultra-small micelles based on ginsenoside Rb1: a potential nanoplatform for ocular drug delivery |
title_sort | novel ultra-small micelles based on ginsenoside rb1: a potential nanoplatform for ocular drug delivery |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461112/ https://www.ncbi.nlm.nih.gov/pubmed/30957571 http://dx.doi.org/10.1080/10717544.2019.1600077 |
work_keys_str_mv | AT limengshuang novelultrasmallmicellesbasedonginsenosiderb1apotentialnanoplatformforoculardrugdelivery AT lanjie novelultrasmallmicellesbasedonginsenosiderb1apotentialnanoplatformforoculardrugdelivery AT lixuefei novelultrasmallmicellesbasedonginsenosiderb1apotentialnanoplatformforoculardrugdelivery AT xinmeng novelultrasmallmicellesbasedonginsenosiderb1apotentialnanoplatformforoculardrugdelivery AT wanghui novelultrasmallmicellesbasedonginsenosiderb1apotentialnanoplatformforoculardrugdelivery AT zhangfan novelultrasmallmicellesbasedonginsenosiderb1apotentialnanoplatformforoculardrugdelivery AT luxiaohong novelultrasmallmicellesbasedonginsenosiderb1apotentialnanoplatformforoculardrugdelivery AT zhuangzengfang novelultrasmallmicellesbasedonginsenosiderb1apotentialnanoplatformforoculardrugdelivery AT wuxianggen novelultrasmallmicellesbasedonginsenosiderb1apotentialnanoplatformforoculardrugdelivery |